Sanofi Consumer Healthcare India Reports Strong Q4 Growth with 35.6% Profit Surge

Sanofi Consumer Healthcare India Limited has announced robust Q4 financial results, demonstrating strong operational performance across key metrics. The company reported significant year-over-year growth in profitability, revenue, and operational efficiency during the quarter.

Financial Performance Highlights

The company delivered impressive financial results for Q4, with net profit reaching ₹678 million compared to ₹500 million in the corresponding quarter of the previous year. Revenue grew substantially to ₹2.3 billion from ₹1.7 billion year-over-year, reflecting strong business momentum.

Financial Metric	Q4 Current	Q4 Previous Year	Growth
Net Profit	₹678 million	₹500 million	35.60%
Revenue	₹2.3 billion	₹1.7 billion	35.29%
EBITDA	₹888 million	₹640 million	38.75%
EBITDA Margin	38.72%	37.08%	+164 bps

Board Meeting and Regulatory Compliance

The Board of Directors meeting was held on April 28, 2026, from 1:00 p.m. to 3:40 p.m., where directors considered and approved the unaudited financial results for the quarter ended March 31, 2026. The company has submitted the required financial documentation to both BSE Limited and National Stock Exchange of India Limited, complying with SEBI Listing Regulations.

Meeting Details	Information
Meeting Date	April 28, 2026
Meeting Duration	1:00 p.m. to 3:40 p.m.
Quarter Ended	March 31, 2026
Regulatory Compliance	SEBI Regulation 33

Sales Performance and Market Growth

The company reported sales of products worth ₹2,063 million for the quarter. Domestic sales demonstrated strong growth of 15.50% aided by successful product relaunches, while export sales surged by 144.40% on a lower base compared to the corresponding quarter of the previous year.

Product Portfolio Impact

The company had voluntarily recalled Depura Kids, Allegra Suspension and Combiflam Suspension in 2024 as a precautionary measure. Combiflam Suspension was successfully relaunched during the quarter ended June 2025, while Allegra Suspension and Depura Kids were relaunched in the quarter ended September 2025. These strategic relaunches contributed to the improved domestic sales performance.

Regulatory Compliance Updates

The company addressed the impact of New Labour Codes notified by the Government of India effective November 21, 2025. An incremental financial impact of ₹24 million was recognized as past service cost, resulting in increased gratuity liability and compensated absences due to changes in wage definitions under Employee Benefits Expense.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.24%	+3.20%	+18.33%	+3.84%	-2.22%	-1.41%

Sanofi Consumer Healthcare India Limited announced the results of its postal ballot conducted under Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on April 23, 2026. The postal ballot sought member approval for four ordinary resolutions related to related party transactions and remuneration matters. Mr. Omkar Dindorkar, Partner at M/s. MMJB & Associates LLP, Practicing Company Secretaries, served as the Scrutinizer for the process and submitted his report on April 23, 2026.

The postal ballot voting period commenced on March 24, 2026, at 9:00 a.m. IST and concluded on April 22, 2026, at 5:00 p.m. IST. The total number of shareholders on the record date stood at 50,742. National Securities Depository Limited (NSDL) provided the remote e-voting facility for the postal ballot process.

All four resolutions were approved with an overwhelming majority by the members of the company. The detailed voting results are as follows:

Resolution	Votes in Favour (%)	Votes Against (%)
Approval for material related party transactions with Opella Healthcare India Private Limited	99.9487	0.0513
Approval for material related party transactions with Opella Healthcare International SAS	99.9415	0.0585
Approval of overall limits of remuneration payable to Non-Executive Director(s)	99.9927	0.0073
Amendment to terms of remuneration of Mr. Himanshu Bakshi (DIN: 08188412), Managing Director	99.9801	0.0199

The total number of shares held across all categories was 23,030,622. For the resolutions related to related party transactions, Promoter and Promoter Group did not vote as per Regulation 23(4) of Listing Regulations, which prohibits related parties from voting on such resolutions. Public Institutions and Public Non-Institutions participated actively in the voting process.

For the remuneration-related resolutions, Promoter and Promoter Group cast 16,414,217 votes, all in favour. Public Institutions cast 4,490,436 votes with 100% support for the Non-Executive Director remuneration resolution and 99.9334% support for the Managing Director remuneration amendment. Public Non-Institutions cast 21,899 votes for the Non-Executive Director resolution and 21,879 votes for the Managing Director resolution.

The Scrutinizer confirmed that there were no invalid votes, abstained votes, or less votes cast on the above resolutions. The resolutions were passed with the requisite majority. The company submitted the voting results signed by the Company Secretary, along with the Scrutinizer's Report dated April 23, 2026, to both BSE Limited and National Stock Exchange of India Limited. The company's scrip code on BSE is 544250 and the trading symbol on NSE is SANOFICONR.